https://biotechmorning.com/news/zipalertinib-second-phase-3-win-egfr-lung-cancer Biotech Morning en 2026-08-14T14:17:52.041Z The Lung Cancer Drug Nobody Saw Coming Just Won Again https://biotechmorning.com/news/ptc-sangamo-fabry-gene-therapy-bankruptcy-auction Biotech Morning en 2026-08-14T14:17:06.196Z PTC Just Bought a Gene Therapy Out of Bankruptcy. It Might Be Brilliant. https://biotechmorning.com/news/sarepta-gene-therapy-nightmare Biotech Morning en 2026-08-14T14:16:14.513Z Sarepta's Gene Therapy Dream Is Turning Into a Nightmare https://biotechmorning.com/news/first-celmod-therapy-fda-approval-iberdomide Biotech Morning en 2026-08-14T14:15:28.901Z The Drug Class That Didn't Exist Until Yesterday https://biotechmorning.com/news/uk-250-million-life-sciences-rd-site Biotech Morning en 2026-08-14T14:14:39.043Z The UK Just Bet £250 Million It Can Out-Science Everyone https://biotechmorning.com/news/lantheus-mk-6240-tau-pet-alzheimers-fda-decision Biotech Morning en 2026-08-14T14:13:59.836Z Alzheimer's Has a Seeing Problem. This Brain Scan Could Fix It. https://biotechmorning.com/news/lilly-449-gambit-zepbound-black-market Biotech Morning en 2026-08-14T14:13:19.009Z Lilly's $449 Gambit to Kill the Zepbound Black Market https://biotechmorning.com/news/lyme-disease-vaccine-back-from-dead Biotech Morning en 2026-08-14T14:12:31.438Z The Vaccine That Got Killed by Fear Is Back From the Dead https://biotechmorning.com/news/vertex-10-billion-crinetics-acquisition-3 Biotech Morning en 2026-08-13T14:20:07.880Z Vertex Just Dropped $10 Billion on a Company You've Probably Never Heard Of https://biotechmorning.com/news/gilead-ouro-medicines-acquisition Biotech Morning en 2026-08-13T14:19:23.428Z Gilead Just Dropped $2.175 Billion on a Company You've Never Heard Of https://biotechmorning.com/news/zipalertinib-rezilient3-egfr-exon20-lung-cancer Biotech Morning en 2026-08-13T14:18:37.773Z The Lung Cancer Mutation That Stumped Every Drug Might Finally Have a Match https://biotechmorning.com/news/crispr-problem-cells-not-scissors Biotech Morning en 2026-08-13T14:17:50.432Z CRISPR's Biggest Problem Isn't the Scissors. It's the Cells. https://biotechmorning.com/news/biotech-1-2-billion-ipo-day-braveheart-kardigan-eikon Biotech Morning en 2026-08-13T14:17:04.898Z Biotech's Big IPO Stretch That Nobody Saw Coming https://biotechmorning.com/news/china-us-clinical-trial-regulatory-divergence Biotech Morning en 2026-08-13T14:16:14.398Z The Two Biggest Drug Markets Are Heading in Opposite Directions https://biotechmorning.com/news/novo-nordisk-amazon-drug-discovery-hub Biotech Morning en 2026-08-13T14:15:35.192Z Novo Nordisk Just Handed Amazon the Keys to Its Drug Lab https://biotechmorning.com/news/lilly-retatrutide-black-market-lawsuits Biotech Morning en 2026-08-13T14:14:49.358Z Lilly's Next Blockbuster Isn't Even Approved Yet. The Black Market Didn't Wait. https://biotechmorning.com/news/vykat-prader-willi-safety-concerns Biotech Morning en 2026-08-13T14:14:06.683Z The First Drug for an 'Always Hungry' Disease Just Hit a Wall https://biotechmorning.com/news/novartis-myricx-bio-adc-acquisition-3 Biotech Morning en 2026-08-13T14:13:24.623Z Novartis Just Paid $1.1 Billion for a Drug That Hasn't Touched a Human https://biotechmorning.com/news/jj-sail-biomedicines-acquisition-option-immunology Biotech Morning en 2026-08-13T14:12:39.044Z J&J Just Put a $2.58 Billion Price Tag on a Company Most People Haven't Heard Of